Advanced search
1 file | 61.19 KB

Cost-utility analysis of ranibizumab (lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium

(2011) VALUE IN HEALTH. 14(3). p.A55-A55
Author
Organization

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 61.19 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Moeremans, K, L Gerlier, S Drieskens, Lieven Annemans, H Brie, M Deruyck, P Faes, and S Vancayzeele. 2011. “Cost-utility Analysis of Ranibizumab (lucentis®) in wet-AMD Based on Real-life Data Collected in the HELIOS Study After Ranibizumab Reimbursement in Belgium.” In Value in Health, 14:A55–A55.
APA
Moeremans, K., Gerlier, L., Drieskens, S., Annemans, L., Brie, H., Deruyck, M., Faes, P., et al. (2011). Cost-utility analysis of ranibizumab (lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium. VALUE IN HEALTH (Vol. 14, pp. A55–A55). Presented at the ISPOR 16th Annual International Meeting.
Vancouver
1.
Moeremans K, Gerlier L, Drieskens S, Annemans L, Brie H, Deruyck M, et al. Cost-utility analysis of ranibizumab (lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium. VALUE IN HEALTH. 2011. p. A55–A55.
MLA
Moeremans, K, L Gerlier, S Drieskens, et al. “Cost-utility Analysis of Ranibizumab (lucentis®) in wet-AMD Based on Real-life Data Collected in the HELIOS Study After Ranibizumab Reimbursement in Belgium.” Value in Health. Vol. 14. 2011. A55–A55. Print.
@inproceedings{2153194,
  articleno    = {abstract PSS14},
  author       = {Moeremans, K and Gerlier, L and Drieskens, S and Annemans, Lieven and Brie, H and Deruyck, M and Faes, P and Vancayzeele, S},
  booktitle    = {VALUE IN HEALTH},
  issn         = {1098-3015},
  language     = {eng},
  location     = {Baltimore, MD, USA},
  number       = {3},
  pages        = {abstract PSS14:A55--abstract PSS14:A55},
  title        = {Cost-utility analysis of ranibizumab (lucentis{\textregistered}) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium},
  volume       = {14},
  year         = {2011},
}

Web of Science
Times cited: